The definitive reference for researchers studying TB-500 — the synthetic Thymosin Beta-4 fragment. Covers actin-sequestration mechanism, tissue repair research applications, comparison with BPC-157, and the Wolverine Stack.
TB-500 is a synthetic peptide corresponding to amino acids 17–23 of Thymosin Beta-4 (Tβ4) — a naturally occurring 43-amino acid protein found in virtually all nucleated cells throughout the body. The specific fragment that TB-500 replicates is the actin-binding domain of Tβ4, which is responsible for the majority of the parent protein's biological activity.
Thymosin Beta-4 was first identified in the thymus gland, but subsequent research has shown it is expressed in almost all tissues, where it serves a fundamental role in regulating actin dynamics — the cytoskeletal machinery that controls cell structure, migration, and division. When tissue is damaged, Tβ4/TB-500 orchestrates the cellular response to begin repair.
TB-500 has been studied in preclinical models for tissue repair across an unusually wide range of injury types: skeletal muscle, tendon, ligament, cardiac muscle, corneal tissue, skin, and nerve tissue. Its systemic distribution — meaning it can be administered distant from an injury site and still travel through the bloodstream to act at the target tissue — makes it uniquely valuable for research designs where local injection is not practical or desirable.
Research Use Only: Corevanta's TB-500 is sold exclusively for laboratory and scientific research. It is not approved for therapeutic use, is not a dietary supplement, and is not intended for human consumption.
TB-500's primary mechanism centers on its ability to sequester G-actin — the monomeric, unpolymerized form of actin. Actin exists in two states in cells: G-actin (free monomers) and F-actin (polymerized filaments). The balance between these states determines how cells can migrate, divide, and respond to injury.
When TB-500 binds G-actin monomers, it creates a concentration gradient at the site of damage — drawing cells toward the injury in a directed manner. This cell migration is the first step in organized tissue repair. At the same time, TB-500 activates integrin-linked kinase (ILK), which triggers the PI3K/Akt survival signaling pathway. This pathway promotes cell survival, inhibits apoptosis of cells near the injury zone, and upregulates matrix metalloproteinases (MMPs) that clear damaged extracellular matrix to make way for new tissue formation.
Additionally, TB-500 promotes the recruitment of bone marrow-derived stem cells to sites of injury — a mechanism that distinguishes it from most other repair peptides. This stem cell mobilization is particularly relevant for research into cardiac tissue repair and chronic tendon injuries where local stem cell pools are limited.
| Mechanism | Effect | Research Implication |
|---|---|---|
| G-actin sequestration | Directed cell migration to injury | Core healing initiation signal |
| ILK / PI3K / Akt activation | Cell survival, MMP upregulation | Matrix clearance, tissue remodeling |
| Angiogenesis induction | New blood vessel formation | Vascular supply to healing tissue |
| Stem cell mobilization | BM stem cells recruited to site | Unique vs. other repair peptides |
| Systemic distribution | Acts at distant injury sites | Enables non-local administration |
TB-500 and BPC-157 are the two most widely studied tissue repair peptides in preclinical research. They are frequently compared, often combined, and sometimes confused. Their mechanisms are fundamentally different.
TB-500 is systemic — it can be administered anywhere and travel to the injury site via circulation, mobilizing stem cells along the way. BPC-157 is predominantly local — proximity of injection to the injury significantly affects outcome. This is why combining them (Wolverine Stack) covers both reach strategies simultaneously.
TB-500 works through actin-cytoskeletal dynamics and ILK/PI3K signaling, producing systemic effects — it can be administered far from the injury and still reach the target. BPC-157 works primarily through nitric oxide (NO) signaling and VEGF upregulation, and acts more locally — the location of administration relative to the injury matters significantly in BPC-157 protocols.
| Feature | TB-500 | BPC-157 |
|---|---|---|
| Origin | Thymosin Beta-4 fragment (endogenous protein) | Gastric juice protection protein |
| Primary mechanism | Actin sequestration + ILK/PI3K | NO signaling + VEGF upregulation |
| Administration range | Systemic — works at distant sites | Local — site of injection matters |
| Stem cell activity | Yes — BM stem cell mobilization | Not demonstrated |
| Gut protection | Limited | Strong mucosal cytoprotection |
| Cardiac tissue data | Stronger preclinical data | Less cardiac-specific data |
| Tendon healing | Both show activity | More published tendon-to-bone data |
Read the full TB-500 vs BPC-157 comparison →
TB-500 is studied across a remarkably wide range of injury and tissue models. The systemic distribution mechanism makes it particularly useful in complex injury models where a single administration route needs to affect multiple tissue types.
Most tissue repair research that uses TB-500 in isolation also investigates the combination with BPC-157 — commonly called the Wolverine Stack. The rationale is mechanistic complementarity: TB-500's systemic G-actin/ILK mechanism handles the broad tissue-level response (cell migration, matrix clearing, stem cell recruitment, angiogenesis), while BPC-157's local NO/VEGF mechanism drives the structural repair (fibroblast proliferation, collagen synthesis, tendon-to-bone healing).
The combination covers both the systemic-level tissue mobilization response and the local structural rebuilding response simultaneously — which more closely mirrors how the body's native repair cascade operates. Research teams studying musculoskeletal healing, sports injury models, and recovery optimization have consistently found more robust outcomes with combined protocols than with either compound alone.
Corevanta's Wolverine Stack provides pre-combined TB-500 + BPC-157 in calibrated vials, eliminating preparation variables across both components in a single product.
Corevanta's TB-500 is supplied as a lyophilized (freeze-dried) powder in sealed borosilicate glass vials.
Corevanta's TB-500 is produced in GMP-compliant facilities and independently tested at ≥99% purity by third-party laboratories using HPLC and LC-MS identity confirmation.
| Specification | Details |
|---|---|
| Purity | ≥99% (HPLC verified) |
| Identity | LC-MS mass spectrometry confirmed |
| Form | Lyophilized powder |
| Available sizes | 5mg, 10mg |
| Certificate of Analysis | Included with shipment |
All Corevanta products are sold exclusively for laboratory research purposes. They are not approved drugs, not dietary supplements, and are not intended for human consumption, therapeutic use, or in-vivo application in humans.